Download PDF

1. Company Snapshot

1.a. Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.It develops a proprietary gene editing platform based on CRISPR technology.The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.


It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia.In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease.It has a research collaboration with Juno Therapeutics, Inc.


to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc.to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio.The company was formerly known as Gengine, Inc.


and changed its name to Editas Medicine, Inc.in November 2013.Editas Medicine, Inc.


was incorporated in 2013 and is based in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on EDIT

Editas Medicine's recent performance was driven by the company's progress in developing transformative in vivo gene editing medicines. The presentation of preclinical data at the American Society of Gene and Cell Therapy Annual Meeting demonstrated therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia. Additionally, the company's announcement of new in vivo data highlighting the potential of its gene upregulation strategy in hematopoietic stem cells (HSCs) at the same meeting further solidified its position in the gene-editing revolution.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Top 3 Genomics Stocks to Consider for Your Portfolio

Nov -18

Source: zacks.com

Card image cap

Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y

Nov -11

Source: zacks.com

Card image cap

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

Nov -10

Source: zacks.com

Card image cap

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov -10

Source: globenewswire.com

Card image cap

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Nov -03

Source: globenewswire.com

Card image cap

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct -14

Source: seekingalpha.com

Card image cap

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct -09

Source: globenewswire.com

Card image cap

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Oct -06

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.47%)

6. Segments

Genome Editing Technology

Expected Growth: 14.47%

Editas Medicine's 14.47% growth in Genome Editing Technology is driven by increasing adoption in gene therapies, partnerships with pharmaceutical companies, and advancements in CRISPR technology. Growing demand for rare genetic disease treatments, expanding pipeline of gene editing programs, and strategic collaborations are also contributing to the growth.

7. Detailed Products

CRISPR Gene Editing

A precise and efficient gene editing technology that enables the modification of genes to treat genetic diseases

CRISPR-Cas9 Gene Regulation

A technology that enables the regulation of gene expression to treat diseases

CRISPR-Cpf1 Gene Editing

A novel gene editing technology that provides an alternative to CRISPR-Cas9

Adeno-Associated Virus (AAV) Vectors

A gene therapy delivery platform that enables the efficient delivery of therapeutic genes to cells

In Vivo CRISPR Gene Editing

A technology that enables the editing of genes within the body to treat diseases

8. Editas Medicine, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Editas Medicine, Inc. is a leader in the gene editing space, but there are other companies and technologies that could potentially substitute its products and services. However, the company's strong intellectual property portfolio and expertise in CRISPR technology provide a competitive advantage.

Bargaining Power Of Customers

Editas Medicine, Inc.'s customers are primarily pharmaceutical and biotechnology companies, which have limited bargaining power due to the company's unique gene editing capabilities and intellectual property.

Bargaining Power Of Suppliers

Editas Medicine, Inc. has a diversified supplier base, and the company's strong financial position and intellectual property portfolio reduce its dependence on any single supplier.

Threat Of New Entrants

The gene editing space is highly competitive, and new entrants could potentially disrupt Editas Medicine, Inc.'s market position. However, the company's strong intellectual property portfolio and expertise in CRISPR technology provide a barrier to entry.

Intensity Of Rivalry

The gene editing space is highly competitive, with multiple companies vying for market share. Editas Medicine, Inc. faces intense competition from established players and new entrants, which could impact its market position and pricing power.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 9.47%
Debt Cost 3.95%
Equity Weight 90.53%
Equity Cost 14.35%
WACC 13.37%
Leverage 10.47%

11. Quality Control: Editas Medicine, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Stoke Therapeutics

A-Score: 4.4/10

Value: 1.3

Growth: 5.2

Quality: 8.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
IGM Biosciences

A-Score: 3.8/10

Value: 9.4

Growth: 7.1

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Editas Medicine

A-Score: 3.3/10

Value: 6.2

Growth: 3.9

Quality: 3.6

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Beam Therapeutics

A-Score: 3.2/10

Value: 6.6

Growth: 3.2

Quality: 3.7

Yield: 0.0

Momentum: 4.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
AIM ImmunoTech

A-Score: 3.1/10

Value: 8.0

Growth: 4.3

Quality: 6.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Precision BioSciences

A-Score: 3.0/10

Value: 6.6

Growth: 5.0

Quality: 3.5

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.42$

Current Price

2.42$

Potential

-0.00%

Expected Cash-Flows